<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036097</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00465; me18Decard</org_study_id>
    <nct_id>NCT04036097</nct_id>
  </id_info>
  <brief_title>Prospective Stratification of Infectious Risks in Multiple Sclerosis</brief_title>
  <acronym>InRIMS</acronym>
  <official_title>Prospective Stratification of Infectious Risks in Multiple Sclerosis (InRIMS-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bangerter-Rhyner Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Chronic Immunodeficiency (CCI) in Freiburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This monocentric study is to identify factors that increase the susceptibility for infections
      and establish a questionnaire-based infection score that allows a prospective stratification
      for infectious risks in patients with multiple sclerosis (MS) (InRIMS-Study). The study will
      utilize a validated, MS-adapted questionnaire and infection diary from the Airway Infection
      Susceptibility (AWIS) study in a regularly followed, prospective cohort of MS patients. It is
      a nested project of the prospective observational Swiss MS Cohort (SMSC) and SUMMIT (Serially
      Unified Multicenter Multiple Sclerosis Investigation) studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AWIS RTI score</measure>
    <time_frame>Baseline</time_frame>
    <description>AWIS RTI score is based on the data collected with the MS-adapted AWIS (MS-AWIS) questionnaire; score varies between 0 (no RTI burden) and 50 (maximal RTI burden)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>infection diary score</measure>
    <time_frame>24 months</time_frame>
    <description>monthly diary RTI score, averaging ten RTI symptom categories with the coding &quot;0&quot; for &quot;no infection reported&quot;, &quot;1&quot; for &quot;reported infection with duration &lt; 2 weeks&quot;, and &quot;2&quot; for &quot;reported infection present with duration &gt;2 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of infection scores between patients receiving Disease Modifying Therapies (DMTs) and those who do not receive DMTs</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of infection scores between patients receiving DMTs and those who do not receive DMTs</description>
  </secondary_outcome>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MS-adapted AWIS questionnaire (MS-AWIS)</intervention_name>
    <description>The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>infection diary (MS-AWIS diary)</intervention_name>
    <description>MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MS patients participating in the SMSC or SUMMIT study with or without DMT
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form (ICF) for the InRIMS-study and Swiss MS Cohort (SMSC)
             and/or Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) study

        Exclusion Criteria:

          -  Not able to sufficiently understand the patient information and questionnaire (German
             language)

          -  MS Patients with long-term antibiotic prophylaxis

          -  MS Patients with known primary immunodeficiency, under chemotherapy due to any
             malignancy or HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Décard, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernhard Décard, Dr. med</last_name>
    <phone>+41 61 265 4151</phone>
    <email>bernhard.decard@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Neurology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Décard, Dr. med</last_name>
      <phone>+41 61 265 4151</phone>
      <email>bernhard.decard@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondary immunodeficiencies</keyword>
  <keyword>disease-modifying treatments (DMT)</keyword>
  <keyword>immunosuppressive therapy</keyword>
  <keyword>serious infection</keyword>
  <keyword>respiratory tract infections (RTI)</keyword>
  <keyword>urinary tract infections</keyword>
  <keyword>infection diary</keyword>
  <keyword>Swiss MS Cohort (SMSC)</keyword>
  <keyword>SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation) studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

